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Abstract
Although the main role of P-glycoprotein (Pgp) is to extrude a broad range of xenochemicals and to protect the organism
against xenotoxicity, it also transports a large range of endogenous lipids. Using mice lacking Pgp, we have investigated the
possible involvement of Pgp in lipid homeostasis in vivo. In a long term study, we have followed the food intake, body
status and lipid markers in plasma and liver of wild-type and mdr1ab
-/- mice over 35 weeks. Pgp-deficient mice showed
excess weight, hypertrophy of adipose mass, high insulin and glucose levels in plasma. Some of these metabolic disruptions
appeared earlier in Pgp-deficient mice fed high-fat diet. Moreover, hepatosteatosis with increased expression of genes
involved in liver detoxification and in de novo lipid synthesis occurred in Pgp-deficient mice. Overall, Pgp deficiency clearly
induced obesity in FVB genetic background, which is known to be resistant to diet-induced obesity. These data reinforce
the finding that Pgp gene could be a contributing factor and possibly a relevant marker for lipid disorder and obesity.
Subsequent to Pgp deficiency, changes in body availabilities of lipids or any Pgp substrates may affect metabolic pathways
that favour the occurrence of obesity. This is of special concern because people are often facing simultaneous exposition to
many xenochemicals, which inhibits Pgp, and an excess in lipid dietary intake that may contribute to the high prevalence of
obesity in our occidental societies.
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Introduction
The P-glycoprotein (Pgp, ABCB1) is a membrane efflux
transporter that belongs to the ATP-binding cassette family,
which in humans is the product of the ABCB1 gene. P-glycoprotein
was first identified as a factor involved in multidrug resistance in
mammalian tumor cells [1] and was subsequently found to be
physiologically expressed at the apical surface of epithelial cells [2].
The main role of Pgp is to actively pump xenobiotics out of cells
and out of the organism. Its widespread tissue distribution and
large substrate specificity confer to this protein a strategic role in
the protection of the tissues and of the whole body against
xenobiotic toxicity [3]. For example, Pgp is located in the intestine
and provides a solid protection by extruding many food
contaminants or naturally occurring dietary substrates back into
the lumen. Similarly, Pgp on the blood-brain-barrier effluxes
compounds out of the brain thereby limiting their neurotoxicity.
By extension, it also limits the intestinal absorption and brain
penetration of drugs which are Pgp substrates, thus limiting their
efficiency. Using Pgp-deficient mice, the pivotal role of Pgp in the
pharmaco- and toxicokinetics of many substrate drugs such as
digoxin, dexamethasone, cyclosporine or ivermectin has been
demonstrated [4-7].
Besides its clear role in the transport of pharmaceuticals and
contaminants, Pgp is also involved in the movement of
endogenous molecules such as cholesterol, phospholipids and
sphingolipids [8] and a variety of steroids [9]. Pgp participates in
the cellular uptake of exogenous cholesterol in recombinant cells
overexpressing Pgp [10]. Pgp is predominantly localised in lipid
rafts which are cholesterol-rich membrane microdomains and it is
involved in cholesterol transbilayer transfer through membranes.
In addition, cholesterol content of membranes affects Pgp
transport activity by modulating the ATPase activity [11-13]. In
vivo, after cholesterol oral loading in Pgp-deficient mice there was
no change in cholesterol intestinal absorption but an increase of
cholesterol ester concentration in the liver [14]. However, until
now, no clear phenotype has been reported for Pgp-deficient
mice in the absence of drug challenge [5] ruling out any
substantial contribution of Pgp in lipid turnover in vivo.B u ti ti s
noteworthy that the FVB genetic background of the available
Pgp-deficient mice is known to be resistant to diet-induced lipid
disorders which certainly make elusive any change in lipid
homeostasis [15].
Indeed, studies in human populations are in favour of a link
between cholesterol levels and ABCB1 gene polymorphisms [16-
18]. Most interestingly, a study performed in a Japanese cohort
revealed that a single nucleotide polymorphism on ABCB1 gene
was associated with obesity [19]. In addition to all these data and
in favour of some involvement of Pgp in lipid homeostasis, during
the course of studies performed in our laboratory, we observed an
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animals.
Given the possibility that Pgp is involved in lipid trafficking and
because accumulation of abdominal fat can foreshadow a
propensity to obesity, the aim of our work was to study the
impact of Pgp deficiency on lipid homeostasis in the whole
organism. Therefore, we have performed a long term study and
followed body weight change and lipid parameters in Pgp-deficient
(mdr1ab
-/-) and wild-type mice. We have then measured the
expression of pivotal genes involved in lipid metabolism (acox, cd36,
fasn, scd-1) and xenobiotic detoxification (cyp2b10 and cyp3a11)
which can be regulated either by lipids or by xenobiotics,
respectively. For the first time, we have demonstrated that the
lack of Pgp is associated with overweight and liver steatosis in mice




In vivo studies were conducted in mice under European laws on
the protection of animals (86/609/EEC). Protocols are performed
under procedure and principal for good clinical practice (CVMP/
VICH 59598). The protocols for experimentation on rodents used
in this manuscript have been approved by the local institutional
animal care and ethics committee which is the ‘‘Direction
De ´partementale des Services Ve ´te ´rinaires de Haute-Garonne’’.
The specific approval number for this study approval is B31555-
25.
Animal housing
Wild-type and the Pgp knock-out mdr1ab
-/- mice with a FVB
genetic background were obtained from Taconic (NY, USA). In
rodents, there are two Pgps encoded by abc1a and abc1b genes and
mdr1ab
-/- mice were deficient for the two gene products [5,6].
Mice were housed at INRA’s transgenic rodent facility at 2262uC
under 12-hour light/dark cycles. Animals sampling was designed
to reduce the influence of interfering parameters such as litter
specificity (seven to nine different litters for a ten animals group).
Mice received a standard chow diet recommended for the
breeding and rearing of rodents (Harlan Teklad TRM Rat/
Mouse Diet; Harlan Teklad, Gannat, France). Water and food
were available ad libitum.
Experimental design
Mice of both genotypes (10–12 males and 10 females per group)
were weighted and the food intake was measured weekly from
weaning to 35 weeks of age. At 25 weeks, food was withdrawn 2 hr
prior to euthanasia and 5 animals of each group were anesthetized
by intraperitoneal administration of xylazine and ketamine
cocktail (53 and 10 mg/kg bw, respectively). Blood was collected
from the orbital sinus vein. Several white adipose pads
(subcutaneous inguinal, perigonadal, perirenal, mesenteric) and
liver were then excised and weighted. At 35 weeks, the rest of the
animals (n=5-6 per groups) were processed as described above for
blood and tissue sampling. Plasma and liver were frozen in liquid
nitrogen and stored at 280uC until analysis.
High-fat diet study
Mice were assigned to normal diet (wild-type n=6 and
mdr1ab
-/- n=6) and high-fat diet HFD (wild-type n=6 and
mdr1ab
-/- n=6) (DIO Research diet, Jackson Laboratory,
Brogaarden, Denmark) for 12 and 25 weeks. Energy contents of
the specific diets were (% kcals): 20% protein, 70% carbohydrate,
and 10% fat for normal diet; 20% protein, 35% carbohydrate, and
45% fat for HFD. Animals were weighted and food intake was
measured all along the experiment. Three animals of each group
were sacrificed at 15 and at 25 weeks. Blood was withdrawn and
plasma and liver were collected and frozen for further analysis.
Plasma analysis
Plasma insulin was quantified by using a kit ELISA for mouse
insulin (EUROBIO, France). Plasma glucose was determined by
the glucose oxidase method. The following parameters: alkaline
phosphatase (ALP), alanine transaminase (ALT), aspartate trans-
aminase (AST), lactate dehydrogenase (LDH), lipase, HDL
cholesterol (HDLc) LDL cholesterol (LDLc), triglycerides and free
fatty acids, were measured using a COBAS-MIRA+ analyser
(Service Phe ´notypage, IFR150/BMT, France).
Lipid analysis in the liver
Lipids were extracted from the liver according to Bligh and
Dyer [20]. Briefly, liver tissue was homogenized in 2 ml of water
and 5 ml of chloroform-methanol (1:1, v/v). Samples were
vortexed and centrifuged at 1500 rpm for 2 minutes at 4uC.
The lower organic phase was removed, dried under nitrogen gas,
taken up in 160 ml ethyl acetate and dried again under nitrogen
gas. The dried lipid samples were dissolved again in 20 ml ethyl
acetate. Triglycerides, total cholesterol and cholesterol esters were
analyzed and quantified by gas chromatography [21] (Plateau de
Lipidomique, IFR150/BMT, Toulouse).
Oil red O staining and histological analysis
A part of the liver was embedding in OCT in Tissue-Teck
(Miles, inc., Kankakee, IL), then the entire block was frozen in
isopentane prior to storage at 280uC. The histological analyses
were performed on serial sections (6 mm thick), fixed in 10%
buffered formalin, stained with oil red O and counterstained with
hematoxylin (original magnification X200, Plateau d’Histopatho-
logie Expe ´rimentale, IFR150/BMT, Toulouse).
Liver mRNA abundance
For RNA extraction, a part of the large lobe of the liver was
collectedand immediatelyfrozeninliquidnitrogenbeforestorageat
280uC. Total RNA was extracted with TRIzol reagent (Invitrogen,
France) from liver tissues. For real-time quantitative PCR (Q-PCR),
totalRNAsamples (2 mg)were reverse-transcribedwith SuperScript
II (Invitrogen). All assays were performed on an ABI Prism 7000
(Applied Biosystems, Courtaboeuf, France) using standard PCR
conditions. Primers and Taqman probes for TATA-box binding
protein tbp (NM_013684), acox (NM_015729), cd36 (NM_007643),
fasn (NM_007988), scd-1 (NM_009127), pltp (NM_011125), cyp7a1
(NM_007825), cyp2b10 (NM_009999), cyp3a11 (NM_007818) were
purchased from Applied Biosystems Assays-on-Demand. Primers
for SYBR Green assays were as follows: tbp-F, 59-ACTTCGTG-
CAAGAAATGCTGAA-39; tbp-R, 59-GCAGTTGTCC-GTGGC-
TCTCT-39; acox-F, 59-CAGACCCTGAAGAAATCATGTGG-
39; acox-R, 59-CAGGAACATGCCCAA-GTGAAG-39; cd36-F,
59- GTTAAACAAAGAGGTCCTTACACATACAG-39; cd36-R,
59- CAGTGAAGGCTCAAAGATGGC-39; fasn-F, 59-AGTCAG-
CTATGAAGCAATTGTGGA-39; fasn-R, 59-CACCCAGACGC-
CAGTGTTC-39; scd-1-F, 59-.CCGGAGACCCCTTAGATCGA-
39; scd-1-R, 59- TAGCCTGTAAAAGATTTCTGCAAACC-39;
pltp-F, 59- GGATTAAAGTGTCCAATGTCTCCTG-39; pltp-R,
59- GTGGAGAAAAAGTTATACATCCTCCTG-39; cyp7a1-F,
59- ACATGGTGACACTTTCACTGTCTTC-39; cyp7a1-R, 59-
GAACTTCTGAAAGCTTAATTGTTTTGG-39; cyp2b10-F, 59-
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GACGTGAAGAAAAGGAAC-AAC-39; cyp3a11-F, 59-.TCACA-
CACACAGTTGTAGGCAG-AA-39; cyp3a11-R, 59-GTTTAC-
GAGTCCCATATCGGTAGAG-39. A pool of all complemen-
tary DNA samples was used to generate calibration curves. All Q-
PCR data were normalized by TATA-box binding protein mRNA
levels.
Statistical analyses
The experimental values are expressed as mean 6 standard
error of the mean (s.e.m). Statistical analyses were performed using
a three-way factorial ANOVA model. A three-way factorial
ANOVA model with repeated measures was used in the case
where more than one observation came from the same animal.
Multiple comparisons of means were performed with Tukey test.
Statistical significance was accepted as p,0.05.
Results
Body weight and food intake in wild-type versus Pgp-
deficient mice
Mice were fed with a standard chow diet throughout the study
and weekly recording of body weight (bw) was performed over 35
weeks. No phenotypic abnormality was observed in young Pgp-
deficient mice for up to 7 weeks of age for female, and 15 weeks of
age for male mice, and they were morphologically undistinguish-
able from age-matched wild-type mice (Fig. 1A and 1B). After
these respective ages, growth curves showed a significant increase
in body weight for females (p,0.05) and males (p,0.001)
mdr1ab
-/- in comparison with wild-type mice. The weight
difference appeared earlier in females, as early as 8 weeks of
age, than in males (18 weeks) but the difference between wild-type
and Pgp-deficient mice was greater in males. Daily food intake was
monitored throughout the experiment and no difference in calorie
intake was observed in mdr1ab
-/- males or females, compared with
wild-type (Fig. 1C and 1D). Given that in our experiment the
weight differences were more pronounced in male mice when
compared with females, the subsequent analyses were performed
in males.
Influence of Pgp deficiency on tissue weight in mice
To get insights into the origin of the overweight phenotype in
Pgp-deficient male mice, liver and white adipose tissue from four
anatomical sites (subcutaneous inguinal, periepididymal, perirenal
and mesenteric) were weighed and their relative contribution to
the body weight were calculated in 25- and 35-week old mice
(Table 1). Liver weight was increased in Pgp deficiency to a similar
extent as whole body weight (Fig. 2A and 2B). In the meantime,
the total mass of white adipose tissues was strongly increased at the
two periods in Pgp-deficient mice (Table 1). At 25 weeks of age,
Figure 1. Time kinetic of body weight and food intake in wild-type versus mdr1ab
-/- mice. The weights were recorded weekly from
weaning to 35-weeks of age for male (Fig. 1A) or female (Fig. 1B) wild-type (open symbols) and mdr1ab
-/- (close symbols) mice fed a standard chow
diet. Results are means 6 s.e.m of 5 to 10 animals. Differences are considered significant when *, p,0.05; **, p,0.01; ***, p,0.001. Daily food intakes
of males (Fig. 1C) and females (Fig. 1D) were calculated weekly by monitoring the total food consumption for wild-type (open symbols) and mdr1ab
-/-
(close symbols) mice, measured as mean food consumption for two to three mice caged together. Results are expressed per gram of body weight
and are the means of 3 values per subgroup.
doi:10.1371/journal.pone.0023614.g001
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teric and periepidydimal fat pads to the bw of mdr1ab
-/- male
mice increased by 2.6-, 2.3-, 2.7- and 1.2-fold, respectively, in Pgp-
deficient mice compared with wild-type. At 35 weeks of age, the
mass of all the white fat pads were increased in Pgp deficiency but
the differences in their relative contribution to the body weight
Table 1. Liver and adipose tissue contributions to the body weight in wild-type versus mdr1ab
-/- mice.
25 weeks 35 weeks
Wild-type (n=6) Mdr1ab
-/- (n=5) F Wild-type (n=6) Mdr1ab
-/- (n=5) F
Weight (g) 31.960.6 43.961.0
a 1.38 36.261.3 44.162.0
b 1.22
Liver (% of bw) 4.9460.28 4.8760.21 0.98 4.6360.16 4.8860.21 1.05
White adipose tissue (% of bw)
subcutaneous inguinal 1.0560.41 2.7260.13
b 2.58 1.3560.20 4.0560.50
a 2.99
perigonadal 1.8660.31 2.1860.22 1.17 2.3760.27 3.5560.17
b 1.50
perirenal 0.4260.09 0.9860.02
b 2.32 0.9160.18 1.2960.10 1.42
mesenteric 0.7560.06 2.0260.22
a 2.69 1.8860.19 2.2660.15 1.21
Total 4.0960.65 7.9160.53
b 1.94 6.5160.69 11.1560.46
a 1.71
Mice were sacrificed at 25 and 35 weeks of age and discrete fat pads from five anatomical sites were dissected and weighed. WAT refers to white adipose tissue. Total
WAT weight represents the sum of the data reported for the four WAT sites considered in the study. Body weight is expressed in gram and tissue weights are expressed
as percentage of body weight. F is the ratio of mdr1ab




Figure 2. Morphological comparison and liver lipid content in wild type and mdr1ab
-/- males. 2A. Whole body. 2B. Respective livers at 35
weeks of age. 2C. Oil red O staining of liver sections. Livers were collected from 25- or 35-week old mice and kept frozen in OCT at 280uC until
analysis. 2D. Lipid content of liver. Total cholesterol (upper histogram) and triglycerides (lower histogram) in liquid-frozen liver samples from 25- and
35- week old mice, were quantified by liquid chromatography in wild-type (open bars) and mdr1ab
-/- (solid bars) males. Results are expressed as
means 6 s.e.m of 5 to 7 mice. Differences are considered significant when p,0.05. ***, p,0.001.
doi:10.1371/journal.pone.0023614.g002
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than earlier, certainly related to the increase in mass of adipose
tissues which was observed with age.
Analysis of enzymes, lipids and glucose in plasma
Biological parameters were measured in mice plasma and were
reported in Table 2. At 25 weeks, none of the plasma parameters
explored were different between Pgp-deficient compared with
wild-type mice, apart from insulin levels, which were strongly
increased (0.5860.39 and 6.6262.11 ng/mL, p,0.05). At 35
weeks, the alkaline phosphatase (ALP) and alanine transaminase
(ALT) activities were increased in Pgp-deficient mice (p,0.01 and
ns, respectively, compared with wild-type). In the mean time,
aspartate transaminase (AST) activity was significantly decreased
(1.5 fold, p,0.05) and lipase and lactate dehydrogenase (LDH)
activities were unchanged. Total cholesterol concentration in
plasma was slightly but significantly higher in mdr1ab
-/- mice
compared with wild-type (4.0360.13 versus 3.4660.17 mmol/L,
p,0.05). At the same time, HDL cholesterol was significantly
enhanced in mdr1ab
-/- mice whereas no change was observed for
plasma LDL cholesterol level. The triglycerides tended to be
decreased in the plasma of Pgp-deficient mice while the free fatty
acid levels were unchanged. Overall, in mdr1ab
-/- mice, plasma
glucose and insulin concentrations were increased compared with
wild-type (1.5- and 23-fold, respectively, p,0.05).
Liver morphology and composition
Major hepatic abnormalities were observed at necropsy of the
Pgp-deficient liver at 35 weeks, with a pale steatotic colour of the
liver and a regular pattern of pale dots displayed on all lobe surfaces
(Fig. 2B). These abnormalities, which are strongly evocative of
hepatic steatosis, were also observed in some of the 25-week old
Pgp-deficient livers (1 over 3). Histological analyses of neutral lipid
in oil red O stained sections of frozen livers, revealed at 25 and 35
weeks clear accumulation of intracellular fat droplets restricted to
the centrilobular area of mdr1ab
-/- livers (Fig. 2C). At 25-weeks,
most of the fat droplets appear bigger when compare to liver at 35
weeks where fat droplets were smaller. Normal hepatocytes were
restricted to periportal zones while wide centrilobular areas
suggested fat storage. At 25 weeks, hepatic triglyceride concentra-
tions were 10-fold greater in mdr1ab
-/- livers than in wild-type and
this difference was maintained at 35 weeks (Fig. 2D, 20.263.7 and
4.360.6 nmol/mg, respectively, p,0.001). In addition, in Pgp
deficient mice at both ages, the total cholesterol content in the liver
was unchanged (Fig 2D, ns) while cholesterol ester concentration
tended to be higher (2-fold, ns, not shown). In addition, the total bile
acids and cholesterol concentrations were significantly higher in
Pgp-deficient mice compared with wild-type (Fig. 3).
Influence of high fat diet on Pgp-deficient mice
In order to test the impact of a high fat diet, a new study was
conducted with mdr1ab
-/- and wild-type mice fed a high fat-diet
(HFD) from weaning to 25 weeks. No difference in body weight
between the two different groups fed HFD was observed during
the experiment suggesting that the overweight observed in Pgp-
deficient mice fed normal chow diet was maximal. By contrast,
wild-type mice fed HFD gained weight compared to those fed
normal chow diet. At 25 weeks, plasma glucose concentrations
were increased in both groups fed HFD when compared to mice
fed normal diet and the increase was greater in the Pgp-deficient
mice (2.1-fold, p,0.01) than in wild-type mice (1.5-fold, p,0.05).
In the mean time, the triglycerides level in plasma were unchanged
by HFD in wild-type mice and were increased in Pgp-deficient
mice fed HFD (Table 3, p,0.05). In Pgp-deficient mice fed HFD,
the liver showed apparent abnormalities as soon as 15 weeks and
at 25 weeks of age. In age-matched animals fed a normal diet, no
liver abnormality was observed in wild-type mice at 25 weeks
while some of Pgp-deficient animals displayed apparent liver
abnormality. Lipids measurements performed in the liver showed
that at 15-week old, Pgp-deficient mice fed HFD tend to have
higher liver triglyceride concentration compared with wild-type
mice (30.166.1 and 18.266.1 nmol/mg, respectively, ns). At 25
Table 2. Biomarker analysis in plasma of wild-type and mdr1ab
-/- mice.
25 weeks 35 weeks
Wild-type Mdr1ab
-/- F Wild-type Mdr1ab
-/- F
ALP (U/L) 18.3610.3 16.065.0 0.87 4.061.5 14.061.2
b 3.50
ALT (U/L) 30.767.4 101.3633.1 3.30 76.6623.6 134.8632.1 1.76
AST (U/L) 107.7627.2 199.0639.6 1.85 530.8670.7 277.6642.7
a 0.52
LDH (U/L) 9846268 20746558 2.11 47646596 38696641 0.81
Lipase (U/L) 21.061.2 26.362.4 1.25 29.062.0 37.6610.2 1.30
Cholesterol (mmol/L) 3.2660.11 3.2360.01 0.99 3.4660.17 4.0360.13
a 1.16
HDLc (mmol/L) 3.0560.09 2.7360.14 0.89 3.1160.18 3.6760.13
a 1.18
LDLc (mmol/L) 0.1060.01 0.1060.01 1.00 0.1660.02 0.1660.02 1.00
Triglycerides (mmol/L) 0.8660.07 0.9260.04 1.07 2.1360.30 1.4660.30 0.69
Free Fatty Acid (mmol/L) 2.8860.12 3.0060.15 1.04 1.1060.05 1.1260.06 1.02
Glucose (mmol/L) 18.361.7 16.161.3 0.88 13.461.1 20.963.0
a 1.56
Insulin (ng/mL) 0.5860.39 6.6262.11
a 11.4 0.1760.02 4.7361.82
a 27.8
Individual plasma samples collected at 25 and 35 weeks were analyzed. Results are expressed as means 6 S.E.M. of 5 analysis for wild-type and mdr1ab
-/- mice, except




ALP: Alkaline phosphatase; ALT: Alanine transaminase; AST: Aspartate transaminase; LDH: Lactate dehydrogenase; HDLc: High density lipoprotein cholesterol; LDLc: Low
density lipoprotein cholesterol.
doi:10.1371/journal.pone.0023614.t002
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both strain fed HFD compared with 15-week old mice, but the
increase was more pronounced in the Pgp-deficient mice than in
wild-type (70.6618.8 and 31.563.7 nmol/mg tissue, respectively,
p,0.01, Fig. 4). In the mean time, a 2-fold increase in cholesterol
ester concentration was measured in the liver of Pgp-deficient mice
compared with wild-type (4.4260.4 and 8.7561.04 ng/mg
respectively, p,0.05, not shown).
Analysis of xenobiotics and lipids target genes
To gain insight into the molecular mechanisms underlying the
effects of Pgp deficiency on hepatic lipid composition, we have
examined the liver expression of several representative genes
involved in lipid homeostasis that are controlled by nuclear
receptors activated by endogenous cholesterol and derivatives
(liver X receptor, LXR) or by fatty acids (peroxisome proliferator-
activated receptors, PPARa and PPARc). We focused on genes
coding for representative enzymes or transporters involved in fatty
acid synthesis (stearoyl-coenzyme A desaturase, SCD-1, and fatty
acid synthase, FASn), lipid uptake (cluster of Differentiation 36,
CD36) and peroxisomal b-oxidation (fatty acyl-CoA oxidase,
ACOX) at 12 and 25 weeks, ages corresponding for Pgp-deficient
mice to normal weight and early overweight phenotype,
respectively. At 12-week of age, only the expression level of scd-1
was significantly increased in mdr1ab
-/- mice when compared with
wild-type mice (2.5-fold, p,0.01, Fig. 5A) while at 25 weeks of age,
simultaneous and significant increases of fasn, scd-1 and cd36
mRNA abundance occur in mdr1ab
-/- mice. At both ages, the
expression of acox was unchanged by Pgp deficiency (Fig. 5B). In
addition, in Pgp-deficient mice at 35 weeks the expression of two
genes cyp7a1 and pltp encoding cholesterol 7 alpha-hydroxylase
(CYP7A), involved in bile acid formation and phospholipid
transfer protein (PLTP), involved in cholesterol elimination were
increased by 2.5-fold in the same way as scd-1.Given that Pgp is
involved in xenobiotic transport, we also explored the expression
of the cytochrome genes cyp2b10 and cyp3a11 which are modulated
by xenosensors such as the constitutive active/androstane receptor
(CAR, NR1I3), and the pregnane X receptor (PXR, SXR,
NR1I2). At 12 weeks, both genes expressions were significantly
increased with a massive increase of cyp2b10 (6-fold, p,0.001,
Fig. 5A). At 25 weeks both genes were 3-fold induced in Pgp-
deficient mice when compared with wild-type mice (Fig. 5B).
Discussion
The toxicological and pharmacological impacts of Pgp have
been well established for many xenobiotic [4–7]. On the basis of its
ability to transport a large range of lipids [8,9], a role in lipid
homeostasis has been evocated for Pgp but has never been clearly
established in vivo.
Our study showed for the first time that the Pgp-deficient mice
fed a standard chow diet developed an overweight phenotype
which occurred earlier and was more pronounced in males than in
females. Besides becoming overweight, a substantial increase of
white abdominal, subcutaneous and visceral adipose tissue mass
was observed with severe hyperinsulinemia which evolved to
hyperglycemia.
Hypertrophy of visceral fat pads is considered as a predictive
factor for lipid metabolic disorders linked to obesity and our data
Figure 3. Lipid content in bile of wild-type and mdr1ab
-/- mice.
Cholesterol and bile acids were quantified in bile in wild-type (open
bars) and mdr1ab
-/- (solid bars) 35-week old male mice. Results are
expressed as means 6 s.e.m of 5 mice. Differences are considered
significant when *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0023614.g003
Figure 4. Influence of high fat diet (HFD) on hepatic
triglyceride concentrations in wild-type and mdr1ab
-/- mice.
Mice were fed with HFD during 25 weeks. Triglycerides have been
quantified in liver samples from 15- or 25-week old wild-type (open
bars) and mdr1ab
-/- (solid bars) mice. Results are expressed as nmol per
mg of liver and are means 6 s.e.m of 3 values at 15-week old and 5 at
25-week old. Differences are considered significant when *, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0023614.g004
Table 3. Influence of high fat diet on plasma glucose and
triglyceride concentrations in wild-type and mdr1ab
-/- mice at
25 weeks of age.
Wild-type Mdr1ab
-/-




Triglyceride (mmol/L) Standard diet 0.8060.07 0.9260.04
HFD 0.7060.03 0.9960.05
a
Mice were fed from weaning to 25 weeks of age whether with a standard chow
diet or a high fat diet (HFD). Glucose and triglycerides were analysed in plasma
samples from wild-type and mdr1ab
-/- mice. Results are expressed as means 6
s.e.m. of 3 to 5 animals.
ap,0.05 when compared with wild-type.
*p,0.05;
**p,0.05, when compared with standard diet.
doi:10.1371/journal.pone.0023614.t003
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propensity of people who are overweight to develop insulin
resistance via the oversupply of fatty acids to tissues. In addition,
liver steatosis appeared clearly in overweight 25-week old Pgp-
deficient mice as evidenced by the massive hepatic triglyceride
accumulation, the increases in cholesterol and biliary acid in bile,
and of ALP and ALT activities in plasma.
When Pgp-deficient mice were fed HFD, deregulation of
metabolism occurred early. Plasma glucose and plasma and
hepatic triglycerides were increased at 15 weeks when compared
with matched wild-type mice fed HFD, revealing that Pgp
deficiency leads to a sensitisation to high-fat diet.
Obesity is multifactorial and overeating is one of the obvious
causes. Indeed, hyperphagia has been observed in several
monogenic disruption obese mouse models (ob [22], db [23], or
agouti [24]). Because the lack of Pgp did not notably influence
feeding behaviour, we exclude overfeeding as the cause of the
obesity in our model.
Obesity occurs in many situations where genes involved in lipid
homeostasis are disrupted. The liver steatosis observed here evokes
up regulation of de novo lipid synthesis in the liver. Indeed, Fasn and
scd-1 expressions were increased in the livers of Pgp-deficient mice
and by their pivotal role in de novo fatty acids synthesis they could
be major contributors of hepatosteatosis. Overexpression of scd-1
was observed in 12-week old Pgp null mice and appeared as an
early event in the onset of lipid disorder. In accordance with our
results, mice lacking SCD-1 are lean with significantly reduced
triglyceride storage in the liver [25] and obesity is related to an
increased expression of scd-1 [15,26]. Similarly, the overexpression
of the well-known ubiquitous scavenger receptor CD36 in the
livers of obese Pgp-deficient mice, may contribute to the onset of
obesity by favouring lipid accumulation in tissues [27,28]. At the
same time, the Acox gene coding for a rate-limiting enzyme in b-
oxidation of fatty acids, was not modified. This suggests that fat
catabolism remains stable in our model.
These data are all the more interesting in that obesity occurred,
as a consequence of Pgp deficiency, in a FVB genetic background
which is known to be resistant to diet-induced obesity. Indeed,
body weight and energy expenditure [15] or hallmark obesity
genes, such as scd-1 [29], were unchanged in normal FVB mice
fed high-fat diet, which is in contrast to C57BL/6 in which HFD
rapidly induces an overweight condition and massive overexpres-
sion of scd-1 [15]. In the same vein, obese transgenic C56BL/6ob/
ob mice had massive increased expression of scd-1 while only a
moderate increase was observed in FVBob/ob [26].
It is obvious that the gene expression profile described above led
to unbalanced lipid homeostasis, contributed to hepatosteatosis
and to the obesity phenotype in the Pgp-deficient mice. Given that
cd36, scd-1 and Fasn are overexpressed in our model and that their
expressions are regulated by the nuclear receptors PPARc for cd36
[30] and LXR for scd-1 and Fasn [31], respectively, we suggest that
the turn-over of activators of these nuclear receptors, i.e., fatty
acid-derived ligands or cholesterol, might be affected in Pgp
deficiency.
The accumulation of triglycerides in the liver was concomitant
with the strong increase in concentrations of bile acids and
cholesterol measured in bile of 35-week old Pgp-deficient mice.
Together with the increase of cyp7a1 expression observed in Pgp-
deficient liver, our data are in accordance with the role of the
enzyme CYP7A1 in bile acid synthesis. In the same vein, given the
role of PLTP in HDL remodelling, the increased expression of pltp
was consistent with the increase of HDL in plasma of Pgp-deficient
mice and attests of abnormal clearance of cholesterol. Cyp7a1 and
pltp are direct targets of LXR [32,33] and our results demonstrate
that the cholesterol metabolic pathway is altered in Pgp deficiency.
In support with our data, another study performed in mdr1ab
-/-
mice fed HFD showed the increased levels of LXR protein and
PLTP activity [34].
Nevertheless, the main role of Pgp is to extrude a broad range of
chemicals and mice lacking Pgp accumulate significantly higher
plasma and tissue concentrations of Pgp substrates such as
glucocorticoids and xenochemicals [7] and certainly food
components. We showed that in Pgp-deficient animals, the
expression of cyp2b10 and cyp3a11 were increased, consistent with
likely increases in the availability of ligands of the hepatic
xenosensors PXR and CAR [35,36]. The list of candidate stimuli
that are transported by Pgp and that can influence P-450s,
through CAR and PXR activation, is long and includes exogenous
Figure 5. Analysis of lipids and xenobiotics target genes
expression in the liver. Relative gene expressions of scd-1, fasn, cd36,
acox, cyp2B10 and cyp3A11 were quantified in liver samples from 12-
week old (Fig. 5A) and 25-week old (Fig. 5B) mice by real-time time PCR.
Similarly, scd-1, cyp7a1 and pltp expressions were quantified in 35-week
old mice (Fig. 5C); wild-type (open bars) and mdr1ab-/- (solid bars).
Values were normalized to TBP gene and expressed as arbitrary unit.
Values shown are means 6 s.e.m (n=3). Differences are considered
significant when p,0.05. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0023614.g005
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and phytooestrogens [39], whose presence depends on the housing
conditions. Indeed in previous works, P-450 genes were shown to
be differentially modulated in Pgp-deficient mice, depending on
the controlled animal housing conditions and the origin of the
standard chow [40].
The activation of CAR or PXR by xenobiotics may be
contributing to obesity in Pgp-deficient mice, especially since the
role of xenosensors has been expanded to the regulation of lipid
metabolism and energy expenditure. Indeed, CAR has been
shown to impact on serum triglyceride levels [41] and PXR
increases hepatic deposit of triglycerides [42]. In addition, they
both increase de novo hepatic lipogenesis by enhancing the
expression thyroid hormone-responsive 14 protein [43]. Whether
PXR and CAR activation, as a consequence of Pgp deficiency, is
a direct cause of obesity and steatosis by disrupting genes
involved in lipid homeostasis or whether gene induction by
xenobiotics and by lipids are two independent pathways, remains
to be determined.
Interestingly, in favour of a role for Pgp in lipid metabolism in
humans, single nucleotide polymorphisms on the Pgp coding
gene ABCB1 have been associated with lipid metabolism disorders
in several independent studies. In hypercholesterolemic patients,
the haplotype G2677T and C3435T on ABCB1 is associated with
higher levels of total and LDL cholesterolemia [18]. Similarly, in
hypercholesterolemic women the ABCB1 allele G2677T/A was
associated with higher levels of total and LDL cholesterol than
those with the more frequent allele G [17]. While in
STANISLAS cohort, G2677T/A polymorphism was associated
with a decrease in plasma total cholesterol but this was in healthy
subjects [16]. Moreover, among 95 polymorphisms of 67
candidate genes, explored in a Japanese cohort including 4252
individuals, only a Pgp gene polymorphism was clearly and
significantly associated with obesity. The body mass index was
greater for individuals with the Pgp gene variant 2677A/T allele
than for those with the GG genotype [19]. Although such an
allele is not associated with deficient Pgp function as we would
have expected in accordance with our results, this study
reinforces our finding of a strong link existing between Pgp and
lipid homeostasis.
In humans, there is no genotype described so far associated with
a full lack of Pgp function. Nevertheless, SNPs in the Pgp gene,
including synonymous SNPs, have been associated with low Pgp
function [44,45]. In addition, therapy is sometimes based on using
drugs which are strong inhibitors of Pgp. As an example, HIV
patients chronically treated with antiretroviral protease inhibitors
frequently elicit a metabolic syndrome including hyperlipidemia,
lipodystrophy, and insulin resistance [46]. Although several
mechanisms have been proposed to explain such drug-induced
deregulations and because protease inhibitors are strong Pgp
inhibitors, we cannot rule out that Pgp inhibition may contribute,
to some extent, to these disorders.
Thus, our results are relevant in the context of people having
low Pgp activity-associated polymorphisms and being exposed
simultaneously to drugs (often used in combination), food
contaminants and natural food components that can be Pgp
inhibitors [47]. With such combinations, substantial inhibition of
the transporter activity may occur and favour the onset of lipid
metabolism disorders. Interestingly, Pgp polymorphism associated
with a complete lack of Pgp function has previously been described
in several canine strains [48,49] but the link between obesity and
Pgp deficiency has never been investigated so far in dogs.
Our data indicate that Pgp-deficient mice develop excess
weight, metabolic disorders, hepatic steatosis that clearly char-
acterise obesity. The metabolic disruption appeared earlier and
was more severe in Pgp-deficient mice fed a high-fat diet. Overall,
Pgp deficiency reverses the resistance to obesity phenotype which
characterizes FVB mice. This is the first time that a clear obese
phenotype has been described in Pgp-deficient mice since they
have been generated [5]. Given the key role of Pgp in controlling
the entrance of a broad range of compounds into the body, we
thus propose that subsequent to Pgp inhibition, lipids or any active
compounds may be absorbed at a higher rate and modulate target
gene expression, affecting metabolic pathways that favour the
occurrence of an obesity syndrome. These data reinforce the
findings that some polymorphisms in the Pgp gene could be a
predisposing factor and may be a relevant marker for obesity.
Indeed, any decrease in Pgp function, due to simultaneous
occurrence of polymorphism and chemical inhibition, may favour
obesity. This can be even worse in occidental societies, where
people are facing a dramatic excess in lipid dietary intake, which if
combined with Pgp inhibition, may accelerate the onset of lipid
metabolic disorders. Deciphering the mechanisms by which Pgp
deficiency is involved in the development of obesity in mice may
help reveal novel physiological functions for Pgp and elucidate
factors associated with the onset of obesity.
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